Molecular foundations of cancer: New targets for intervention

Nature Medicine

Volumn 1, Issue 4, 1995, Pages 309-320

  Karp, Judith E ^a   Broder, Samuel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CARCINOGENESIS; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMAL; CELL CYCLE; CYCLIN-DEPENDENT KINASES; CYCLINS; HUMAN; MOLECULAR BIOLOGY; NEOPLASMS; PROTEIN P53;

EID: 0028915222     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0495-309     Document Type: Review

References (137)

1. Nurse, P. Universal control mechanism regulating onset of M-phase. Nature 344, 503-508 (1990).
2. Pines, J. & Hunter, T. p34 The S and M kinase. New Biologist 2, 389-401 (1990).
3. Reed, S.I. Gl-specific cyclins: In search of an S-phase-promoting factor. Trends Genet. 7, 95-99 (1991).
4. Sherr, C.J. Mammalian G, cyclins. Cell 73, 1059-1065 (1993).
5. Dulic, V., Lees, E. & Reed, S.I. Association of human cyclin E with a periodic G,-S phase protein kinase. Science 257, 1958-1961 (1992).
6. Reznitzky, D., Gossen, M., Bujard, H. & Reed, S.I. Acceleration of the CJS phase transition by expression of cyclins D1 and E with an inducible system. Mol. cell. Biol. 14, 1669-1679 (1994).
7. Matsushime, H., Roussel, M.F., Ashmun, R.A. & Sherr, C.J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65, 701-713 (1991).
8. Dowdy, S.F. et al. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73, 499-511 (1993).
9. Hinds, P.W. et al. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70, 993-1006 (1992).
10. Motokura, T. et al. A novel cyclin encoded by a bell- linked candidate oncogene. Nature 350, 512-515 (1991).
11. Motokura, T. & Arnold, A. Cyclin D and oncogenesis. Curr. Opin. Genet. Dev. 3, 5-10 (1993).
12. Chu, E.W. & Rabson, A.S. Chimerisrn in lymphoid cell culture lines derived from lymph node of marmoset infected with Herpesvirus saimiri. J. natn. Cancer Inst. 48, 771-775 (1972).
13. Nicholas, J., Cameron, K.R. & Honess, R.W. Herpesvirus saimiri encodes homologues of G protein-coupled receptors and cyclins. Nature 355, 362-365 (1992).
14. Chang, Y. et al. Identification of heïpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865-1869 (1994).
15. Leach, F.S. et al. Amplification of cyclin genes in colorectal carcinomas. Cancer Res. 53, 1986-1989 (1993).
16. Bosl, GJ. et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J. natn. Cancer Inst. 86, 349-355 (1994).
17. Juliusson, G. et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. New Engl. J. Med. 323, 720-728 (1990).
18. Xiong, Y., Menninger, J., Beach, D. & Ward, D.C. Molecular cloning and chromosome mapping of CCND genes encoding human D-type cyclins. Genomics 13, 575-584 (1992).
19. Keyomarsi, K. & Pardee, A.B, Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. natn. Acad. Sci. U.S.A. 90, 1112-1116(1993).
20. Keyomarsi, K. et al. Cyclin E, a potential prognostic marker for breast. cancer. Cancer Res. 54, 380-385 (1994).
21. Greenblatt, M.S., Bennett, W.P., Hollstein, M. & Harris, C.C. Mutations in the pS3 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878 (1994).
22. Levine, A.J., Momand, J. & Finlay, C.A. The p53 tumour suppressor gene. Nature 351, 453-455 (1991).
23. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250, 1233-1238 (1990).
24. Jolly, K.W. et al. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 9, 97-102 (1994).
25. Wong, M. & Gruber, J. Viral interactions with the p53 gene in human cancer: NCI workshop. J. natn. Cancer Inst 86, 177-182 (1994).
26. Speir, E. et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265, 391-394 (1994).
27. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
28. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V. & Kastan, M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. natn. Acad. Sci. USA 89, 7491-7495 (1992).
29. Maltzman, W. & Czyzyk, L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol cell Biol 4, 1689-1694 (1984).
30. Waldmann, T.A., Misiti, J., Nelson, D.L. & Kraemer, K.H. Ataxia-telangiectasia: A multisystem hereditary disease with immunodeficiency, impaired organ maturation, X-ray hypersensitivity, and a high incidence of neoplasia. Ann. intern. Med. 99, 367-379 (1983).
31. Kastan, M.B. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD 45 is defective in ataxia-telangiectasia. Cell 71, 587-597 (1992).
32. El-Deiry W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
33. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi & S.J. Elledge. The p21 cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
34. Dulic, V. et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023 (1994)
35. Slebos, R.J.C. et al. p53-dependent Gj arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. natn. Acad. Sci. U.S.A. 91, 5320-5324 (1994).
36. Xiong, Y. et al. p21 is a universal inhibitor of cyclin kinases. Nature 366, 70-704 (1993).
37. Waga, S., GJ. Hannon, D. Beach & B. Stillman. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574-578 (1994).
38. Smith, M.L. et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266, 1376-1380 (1994).
39. Hall, P.A. et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J. Pathol 162, 285-294 (1990).
40. Keim, D., N. Hailat, D. Hodge & S.M. Hanash. Proliferating cell nuclear antigen expression in childhood acute leukemia. Blood 76, 985-990 (1990).
41. Shin, D.M. et al. Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: A potential biomarker. J. natn. Cancer Inst. 85, 971-978 (1993).
42. KlpI, a cycIin-CDK inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8, 9-22 (1994).
43. Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994).
44. Toyoshima, H. & T. Hunter. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78, 67-74 (1994).
45. Hengst, L., V. Dulic, J.M. Slingerland, E. Lees & S.I. Reed. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. natn. Acad. Sci. U.S.A. 91, 5291-5295 (1994).
46. Slingerland, J.M. et al. A novel inhibitor of cyclin-cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol cell. Biol 14, 3683-3694 (1994).
47. Wakefield, L.M. & Sporn, M.B. Supression of carcinogenesis: A role for TGF-beta and related molecules in the prevention of cancer, in: Tumor Suppressor Genes (ed. Klein, G.) 217-243 (Marcel Dekker, Inc., New York, 1990).
48. Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440 (1994).
49. Serrano, M., G.J. Hannon & D. Beach. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707 (1993).
50. Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756 (1994).
51. 1NK4in human cancer. Proc. natL Acad. Sci. U.S.A. 91, 11045-11049 (1994).
52. Ogawa, S. et al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (pl6) gene in human leukemias. Blood 84, 2431-2435 (1994).
53. Cheng, J.Q. et al. pl6 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54, 5547-5551 (1994).
54. INK4Bis a potential effector of TGF-beta-induced cell cycle arrest. Nature 371, 257-261 (1994).
55. Peters, G. Stifled by inhibitors. Nature 371, 204-205 (1994).
56. Koff, A., M. Ohtsuki, K. Polyak, J.M. Roberts & J. Massague. Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-beta. Science 260, 536-539 (1993).
57. Lynch, H, T, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control. Part I. Cancer Genet. Cytogenet. 53, 143-160 (1991).
58. Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A., Goldgar, D.E. & the Breast Cancer Linkage Consortium. Risks of cancer in BRCA-1 mutations carriers. Lancet 343, 692-695 (1994).
59. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. New Engl. J. Med. 319, 525-532 (1988).
60. Rustgi, A.K. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. New Engl. J. Med. 331, 1694-1702 (1994).
61. Kinzler, K.W, et al. Identification of FAP locus genes from chromosome 5q21. Science 253, 661-665 (1991).
62. Powell, S.M. et al. APC mutations occur early during colorectal tumorigenesis. Nature 359, 235-237 (1992).
63. Aaltonen, L.A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812-816 (1993).
64. Fishel, R.A. et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1027-1038 (1993).
65. Leach, F.S. et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75, 1215-1225 (1993).
66. Peltomaki, P. et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 260, 810-812 (1993).
67. Parsons, R. et al. Hypermutabiíity and mismatch repair deficiency in RER+ tumor cells. Cell 75, 1227-1236 (1993).
68. Thibodeau, S., G. Bren, & D. Schaid. Microsatellite instability in cancer of the proximal colon. Science 260, 816-818 (1993).
69. Watson, P., H.F.A. Vasen, J.P. Mecklin, H. Jarvinen & H.T. Lynch. The risk of endometrial cancer in hereditary nonpoìyposis colorectal cancer. Am. J. Med. 96, 516-520 (1994).
70. Fishel, R., Ewel, A. & Lescoe, M.K. Purified human MSH2 protein binds to DNA mismatched nucleotides. Cancer Res. 54, 5539-5542 (1994).
71. Prolla, T.A., Christie, D.M. & Liskay, R.M. Dual requirement in yeast DNA mismatch repair for MLH1 and PMS1, two homologs of the bacterial mutL gene. Mol. cell. Biol 14, 407-415 (1994).
72. Prolla, T.A., Pang, Q., Alani, E., Kolodner, R.D. & Liskay, R.M. MLH1, PMS1 and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science 265, 1091-1093 (1994).
73. Bronner, C.E. et al. Mutation in the DNA mismatch repair gene homologue MLH1 is associated with hereditary non-polyposis colon cancer. Nature 368, 258-261 (1994).
74. Papadopoulos, N. et al. Mutation of a mutL homolog in hereditary colon cancer. Science 263, 1625-1629 (1994).
75. Nicolaides, N.C. et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371, 75-80 (1994).
76. Liu, B. et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genet. 9, 48-55 (1995).
77. Powell, S.M. et al. Molecular diagnosis of familial adenomatous polyposis. New Engl. J. Med. 329, 1982-1987 (1993).
78. Nayfleld, S.G., J.E. Karp, L.G. Ford, F.A. Dorr & B.S. Kramer. J. natn. Cancer. Inst. 83, 1450-1459 (1991).
79. Mao, L. et al. Microsatellite alterations as clonal markers for the detection of human cancer. Proc. natn. Acad. Sci. U.S.A. 91, 9871-9875 (1994).
80. Rubinfeld, B. et al. Association of the APC gene product with beta-catenin. Science 262, 1731-1734 (1993).
81. Su, L-K., B. Vogelstein & K.W. Kinzler. Association of the APC tumor supressor protein with catenins. Science 262, 1734-1737 (1993).
82. Hall, J.M. et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science 250, 1684-1689 (1990).
83. Futreal, P.A. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120-122 (1994).
84. Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
85. Wooster, R. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13ql2-13. Science 265, 2088-2090 (1994).
86. Weber, B.L. Susceptibility genes for breast cancer. New Engl. j. Med. 331, 1523-1524 (1994).
87. Goldgar, D.E. et al. A large kindred with 17q-linked breast and ovarian cancer: Genetic, phenotypic, and genealogical analysis. J. natn. Cancer Inst. 86, 200-209 (1994).
88. Castilla, L.H. et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nature Genet. 8, 387-391 (1994).
89. Friedman, L.S. et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genet. 8, 399-404 (1994).
90. Simard, J. et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet. 8, 392-398 (1994).
91. Carter, B.S. et al. Hereditary prostate cancer: Epidemiologic and clinical features. J. Urol. 150, 797-802 (1993).
92. Bova, G.S. et al. Homozygous deletion and frequent allelic loss of chromsome 8q22 loci in prostate cancer. Cancer Res. 53, 3869-3873 (1993).
93. Lee, W.-H. et al. Cytidine methylation of regulatory sequences near the pi class glutathione-S-transferase gene accompanies human prostatic carcinogenesis, Proc. natn. Acad. Sci. U.S.A. 91, 11733-11737 (1994).
94. b, ïin prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. natn. Cancer. Inst. 86, 1140-1145 (1994).
95. Morton, R.A., Ewing, C.M., Nagafuchi, A., Tsukita, S., Isaacs, W.B. Reduction in E-cadherin levels and deletion of the a-catenin gene in human prostate cancer cells. Cancer Res. 53, 3585-3590 (1993).
96. Morton, R.A. et al. Assignment of the human a-catenin gene to chromosome 5q21-q22. Genomics 19, 188-190 (1994).
97. Umbas, R. et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54, 3929-3933 (1994).
98. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1319 (1993).
99. Gnarra, J. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85-90 (1994).
100. Herman, J.G. et al. Silencing of the VHL tumor-suppresor gene by DNA methylation in renal carcinoma. Proc. natn. Acad. Sci. U.S.A. 91, 9700-9704 (1994).
101. Zbar, B. et al. Hereditary papillary renal cell carcinoma. J. Urol. 151, 561-566 (1994).
102. Benezra, M., I. Vlodasky, R. Ishai-Michaeli, G. Neufeld, R. Bar-Shavit. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood 81, 3324-3331 (1993).
103. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31 (1995).
104. Folkman, J. et al. A heparin-binding anigogentc protein-basic fibroblast growth factor-is stored within basement membrane. Am. J. Pathol. 130, 393-400 (1988).
105. Vlodasky, I. et al. Extracellular matrix-resident basic fibroblast growth factor: Implication for the control of angiogenesis. J. cell. Biochem. 45, 167-176 (1991).
106. Nabel, E.G. et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 362, 844-846 (1993).
107. Koch, A.E. et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258, 1798-1801 (1992).
108. Kim, K.J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
109. Plate, K.H., Breier, G., Weich, H.A., Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848 (1992).
110. Shweiki, D., A. Itin, D. Soffer, E. Keshet. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992).
111. Aiello, L.P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl. J. Med. 331, 1480-1487 (1994).
112. Browning, P.J. et al. Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency cirus-l-infected individuals and normal controls. Blood 84, 2711-2720 (1994).
113. Ensoli, B. et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243, 233-236 (1989).
114. Ensoli, B. et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371, 674-680 (1994).
115. Delli-Bovi, P. et al. Processing, secretion and biological properties of a novel growth factor of the fibroblast growth factor family with oncogenic potential. Mol. cell. Biol. 8, 2933-2941 (1988).
116. Halaban, R., B.S. Kwon, S. Ghosh, P. Delli Bovi & A. Baird. bFGF as an autocrine growth factor for human melanomas. Oncogene Res. 3, 177-186 (1988).
117. Brunner, G., H. Nguyen, J. Gabrilove, D.B. Rifkin, E.L. Wilson. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 81, 631-638 (1993).
118. Aman, M.J. et al. Type-I interferons are potent inhbitors of interleukin-8 prodcution in hematopoietic and bone marrow stromal cells. Blood 82, 2371-2378 (1993).
119. Nguyen, M., H. Watanabe, A.E. Budson, J.P. Richie & J. Folkman. Elevated levels of angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. natn. Cancer Inst. 85, 241-242 (1993).
120. Nguyen, M. et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. natn. Cancer Inst. 86, 356-361 (1994).
121. Gasparini, G. et al. Tumora microvessel density, p53 expression, tumor size, and peritumoral lymphatic veil invasion are relevant prognostic markers in node-negative breast carcinoma. J. clin. Oncol. 12, 454-466 (1994).
122. Weidner, N. et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast cancer. J. natn. Cancer Inst. 84, 1875-1887 (1992).
123. Guidi, A.J., Fischer, L. Harris, J.R., Schltt, S.J. Microvessel density and distribution in ductal carcinoma in situ of the breast. J. natn. Cancer Inst. 86, 614-619 (1994).
124. Olson, T.A., Mohanraj, D., Carson, L.F., Ramakrishnan, S. Vascular permeability factor gene expression in normal and neoplastic ovaries. Cancer Res. 54, 276-280 (1994).
125. Cancer Statistics Review 1973-1991. National Cancer Institute, Division of Cancer Prevention and Control. NIH publication #94-2789, 1994.
126. Dameron, K.M., O.V. Volpert, M.A. Tainsky, N. Bouck. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584 (1994).
127. O'Reilly, M.S. et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastses by a Lewis lung carcinoma. Cell 79, 315-328 (1994).
128. Ezekowitz, R.A.B., Mulliken, J.B., Folkman, J. Interferon alfa-2a for life-threatening hemangiomas of infancy. New Engl. J. Med. 326, 1456-1463 (1992).
129. Myers, C. et al. Role of suramin in cancer biology and treatment, in: Molecular Foundations of Oncology (ed. Broder, S.) 419-431 (Williams, Wilkins, Baltimore, 1991).
130. Ingber, D. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557 (1990).
131. Burrows, F.J., Thorpe, P.E.Vascular targeting-a new approach to the therapy of solid tumors. Pharmac. Ther. 64, 155-174 (1994).
132. Rettig, W.J. et al. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. natn. Acad. Sci. U.S.A. 89, 10832-10836 (1992).
133. Brooks, P.C., R.A.F. Clark, Cheresh, D.A. Requirement of vascular integrin a.t. for angiogenesis. Science 264, 569-571 (1994).
134. Brooks, P.C. et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994).
135. Burrows, F.J. Thorpe, P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. natn. Acad. Sci. U.S.A. 90, 8996-9000 (1993).
136. Simons, M., Edelman, E.R., DeKeyser, J.-L., Langer, R.D., Rosenberg, R.D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70 (1992).
137. Chang, M.W. et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267, 518-522 (1995).